Institutional Biosafety Committee
The National Institutes of Health's NIH Guidelines (NIH Guidelines for Research Involving Recombinant DNA Molecules) require the use of an Institutional Biosafety Committee (IBC) to oversee any activities that involve biohazardous materials, especially research activities that involve recombinant or synthetic nucleic acid molecules.
When conducting research that uses recombinant DNA, investigators are responsible for obtaining IBC approval.
Possible activities that require IBC approval:
- Infectious agents.
- Carcinogens.
- Human or non-human-primate materials (body fluids, cell lines, tissues).
- Biotoxins.
All applicable research activities must be reviewed by the IBC, regardless of the source of funding for the proposed project.
- Prisma Health is registered with the NIH’s Institutional Biosafety Committee Registration Management System (IBC-RMS).
- Prisma Health contracts with Western Institutional Review Board (WIRB) to provide IBC services.
- In accordance with NIH protocol, Prisma Health has the appropriate personnel in place.
Prisma Health and NIH protocol and personnel responsibilities include:
- Reporting to the IBC and the institution any significant problems.
- Violations of the NIH Guidelines.
- Any significant research-related accidents or illnesses.
- Developing emergency plans for handling accidental spills.
- Personnel contamination.
- Laboratory accidents.
- Providing technical advice to Principal Investigators (PI) and the IBC on research safety procedures.
Contact us
These or related questions or concerns regarding IBC services at Prisma Health may be directed to:
Jan Kueber, Manager, CRU, Prisma Health in the Upstate
Jan.Kueber@PrismaHealth.org
Additional information
NIH Institutional Biosafety Committee Registration Management System
NIH Guidelines